1Bestermann, W, Houston, MC, Basile, J, et al. (2005) Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 329, 292–305.
2Bloedon, LT & Szapary, PO (2004) Flaxseed and cardiovascular risk. Nutr Rev 62, 18–27.
3Fukumitsu, S, Aida, K, Ueno, N, et al. (2008) Flaxseed lignan attenuates high-fat diet-induced fat accumulation and induces adiponectin expression in mice. Br J Nutr 100, 669–676.
4Prasad, K (2007) A study on regression of hypercholesterolemic atherosclerosis in rabbits by flax lignan complex. J Cardiovasc Pharmacol Ther 12, 304–313.
5Ratnayake, WM & Gilani, GS (2003) Protective effects of flax meal against hypercholesterolemia and hypertriglyceridemia in rats. J Am Coll Nutr 22, 157–164.
6Prasad, K (2005) Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Atherosclerosis 179, 269–275.
7Jenkins, DJ, Kendall, CW, Vidgen, E, et al. (1999) Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Am J Clin Nutr 69, 395–402.
8Lucas, EA, Wild, RD, Hammond, LJ, et al. (2002) Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab 87, 1527–1532.
9Hall, C III & Tulbek, MC Xu Y (2006) Flaxseed. Adv Food Nutr Res 51, 1–97.
10Pan, A, Sun, J, Chen, Y, et al. (2007) Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial. PLoS ONE 2, e1148.
11Zhang, W, Wang, X, Liu, Y, et al. (2008) Dietary flaxseed lignan extract lowers plasma cholesterol and glucose concentrations in hypercholesterolaemic subjects. Br J Nutr 99, 1301–1309.
12Axelson, M, Sjovall, J, Gustafsson, BE, et al. (1982) Origin of lignans in mammals and identification of a precursor from plants. Nature 298, 659–660.
13Hu, C, Yuan, YV & Kitts, DD (2007) Antioxidant activities of the flaxseed lignan secoisolariciresinol diglucoside, its aglycone secoisolariciresinol and the mammalian lignans enterodiol and enterolactone in vitro. Food Chem Toxicol 45, 2219–2227.
14Bhathena, SJ & Velasquez, MT (2002) Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 76, 1191–1201.
15Kushiro, M, Masaoka, T, Hageshita, S, et al. (2002) Comparative effect of sesamin and episesamin on the activity and gene expression of enzymes in fatty acid oxidation and synthesis in rat liver. J Nutr Biochem 13, 289–295.
16Martin, G, Duez, H, Blanquart, C, et al. (2001) Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest 107, 1423–1432.
17Mezei, O, Banz, WJ, Steger, RW, et al. (2003) Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 133, 1238–1243.
18Schoonjans, K, Staels, B & Auwerx, J (1996) Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37, 907–925.
19Friedewald, WT, Levy, RI & Fredrickson, DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499–502.
20Roglans, N, Sanguino, E, Peris, C, et al. (2002) Atorvastatin treatment induced peroxisome proliferator-activated receptor α expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 302, 232–239.
21Shimomura, I, Hammer, RE, Richardson, JA, et al. (1998) Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 12, 3182–3194.
22Bierenbaum, ML, Reichstein, R & Watkins, TR (1993) Reducing atherogenic risk in hyperlipemic humans with flax seed supplementation: a preliminary report. J Am Coll Nutr 12, 501–504.
23Prasad, K (1999) Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 99, 1355–1362.
24Kersten, S (2001) Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2, 282–286.
25Bhathena, SJ, Ali, AA, Haudenschild, C, et al. (2003) Dietary flaxseed meal is more protective than soy protein concentrate against hypertriglyceridemia and steatosis of the liver in an animal model of obesity. J Am Coll Nutr 22, 157–164.
26Prasad, K, Mantha, SV, Muir, AD, et al. (1998) Reduction of hypercholesterolemic atherosclerosis by CDC-flaxseed with very low α-linolenic acid. Atherosclerosis 136, 367–375.
27Lemay, A, Dodin, S, Kadri, N, et al. (2002) Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women. Obstet Gynecol 100, 495–504.
28Cunnane, SC, Ganguli, S, Menard, C, et al. (1993) High α-linolenic acid flaxseed (Linum usitatissimum): some nutritional properties in humans. Br J Nutr 69, 443–453.
29Gowri, MS, Reaven, GM & Azhar, S (1999) Masoprocol lowers blood pressure in rats with fructose-induced hypertension. Am J Hypertens 12, 744–746.
30Hemmings, SJ & Barker L (2004) The effects of dietary flaxseed on the Fischer 344 rat: I. Development, behaviour, toxicity and the activity of liver γ-glutamyltranspeptidase. Cell Biochem Funct 22, 113–121.